UNSPSC 51342804: Atevirdine mesilate or mesylate

This classification denotes a reverse transcriptase inhibitor with the molecular formula C21H25N5O2.CH4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier A948D8673W. The term atevirdine mesilate is a United States Adopted Name designation. Most nations, for tariff and trade purposes, schedule atevirdine mesylate under HS 29335995. As of Q4 2014, ATEVIRDINE MESYLATE remains US FDA's Preferred Term for this commodity. Atevirdine mesylate bears US NLM identifiers UMLS ID C0210242 and NCI Concept Code C73148.

SMILES: CCNC1CCCNC1N2CCN(CC2)C(=O)C3CC4CC(CCC4[NH]3)OC.CS(=O)(=O)O.

UNSPSC 51342804 Atevirdine mesilate or mesylate is a Commodity code that represents a specific pharmaceutical active ingredient used in antiviral therapies. Recent state and local procurement activity under this code shows minimal direct solicitation for the ingredient itself; instead, state and local health agencies are procuring finished pharmaceutical products and related health intervention supplies through piggyback contracts and competitive bidding processes. The issuing bodies include state health departments and county public health authorities purchasing through cooperative purchasing vehicles such as MMCAP Infuse and direct IFB processes to support emergency preparedness, disease prevention, and community health initiatives.

Activity under this code appears concentrated in Florida and Illinois based on recent postings. The Illinois Department of Public Health awarded a pharmaceutical warehouse piggyback contract through MMCAP Infuse to Chartwell Rx LLC on August 28, 2026, for antibiotic products including Doxycycline Hyclate and Ciprofloxacin Hydrochloride totaling $2,999,999.11 over the contract life with a 12-month initial term and two renewal options. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida, under an initial two-year term with a one-year renewal option. Both opportunities reflect state and local reliance on cooperative purchasing frameworks and fixed-term contracts with renewal provisions for pharmaceutical and health-protection supply chains.